 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...

PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

PepGen announces presentations of data on EDO platform

- EDO platform observed to drive 25-fold higher level of oligonucleotide delivery to myotube nuclei compared to naked oligonucleotide - - EDO technology enabled delivery of therapeutic...

PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences

The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to PGN-EDODM1 for the treatment of Myotonic Dystrophy Type 1 (DM1)BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- PepGen Inc...

PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1

PepGen Inc. (NASDAQ:PEPG  Get Free Report) shares were up 2.5% on Friday . The stock traded as high as $6.63 and last traded at $6.46. Approximately 9,635 shares traded hands during trading, a...

PepGen (NASDAQ:PEPG) Trading Up 2.5%

BOSTON, Sept. 01, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...

PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference

HC Wainwright reiterated their buy rating on shares of PepGen (NASDAQ:PEPG Free Report) in a research note issued to investors on Wednesday, Benzinga reports. HC Wainwright currently has a $26.00 price target on the stock. HC Wainwright also issued estimates for PepGens FY2023 earnings at ($2.93) ...

PepGen (NASDAQ:PEPG) Given Buy Rating at HC Wainwright

PepGen Inc. (NASDAQ:PEPG Free Report) Investment analysts at HC Wainwright decreased their FY2023 earnings per share estimates for shares of PepGen in a research report issued on Wednesday, August 9th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($2.93) per ...

HC Wainwright Brokers Cut Earnings Estimates for PepGen Inc. (NASDAQ:PEPG)

PepGen Inc. (NASDAQ:PEPG  Free Report)  Investment analysts at HC Wainwright decreased their FY2023 earnings per share estimates for shares of PepGen in a research report issued on Wednesday, August 9th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of...

PepGen Inc. (NASDAQ:PEPG  Free Report)  Leerink Partnrs decreased their Q3 2023 earnings estimates for shares of PepGen in a research report issued to clients and investors on Tuesday, August 8th. Leerink Partnrs analyst J. Schwartz now expects that the company will earn ($0.93) per ...

PepGen Inc. Forecasted to Post Q3 2023 Earnings of ($0.93) Per Share (NASDAQ:PEPG)

PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.

Watchers	17
52-Wk Low	$4.71
52-Wk High	$20.00

Market Cap	$120.97M
Volume (M)	31,917.00
52-Wk High	$20.00
52-Wk Low	$4.71

PEPG PepGen Inc

About

Feed

News

Earnings

Fundamentals